PIK3CA and breast cancer: One Phase III trial will assess the efficacy of GDC-0077 in combination with palbociclib and fulvestrant compared to placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant HR + BC (NCT04191499).